Davide Melisi
Overview
Explore the profile of Davide Melisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
3814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Future Oncol
. 2025 Feb;
21(7):765-774.
PMID: 39935331
No abstract available.
2.
Pietrobono S, Bertolini M, De Vita V, Sabbadini F, Fazzini F, Frusteri C, et al.
NPJ Precis Oncol
. 2024 Oct;
8(1):246.
PMID: 39478186
The TGFβ receptor inhibitor galunisertib showed promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the phase 2 H9H-MC-JBAJ study. Identifying biomarkers for this treatment remains essential. Baseline plasma...
3.
Merz V, Maines F, Marcucci S, Sartori C, Frisinghelli M, Trentin C, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):347.
PMID: 38990367
Background: Therapeutic approach used for pancreatic ductal adenocarcinoma is usually translated also for the rarer acinar counterpart, which shows a different mutational landscape nevertheless. While dMMR/MSI-H status is rare in...
4.
Giordano G, Milella M, Landriscina M, Bergamo F, Tirino G, Santaniello A, et al.
Cancer Med
. 2024 Jun;
13(12):e7345.
PMID: 38924262
Background: Pancreatic cancer (PC) first-line therapy often consists of polychemotherapy regimens, but choosing a second-line therapy after disease progression, especially following first-line FOLFIRINOX, remains a clinical challenge. This study presents...
5.
Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al.
Gastric Cancer
. 2024 Jun;
27(4):672-674.
PMID: 38884884
No abstract available.
6.
Cressoni C, Malandra S, Milan E, Boschi F, Nicolato E, Negri A, et al.
Biomacromolecules
. 2024 May;
25(6):3741-3755.
PMID: 38783486
The development of efficient and biocompatible contrast agents is particularly urgent for modern clinical surgery. Nanostructured materials raised great interest as contrast agents for different imaging techniques, for which essential...
7.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, et al.
BMC Cancer
. 2024 May;
24(1):563.
PMID: 38711003
No abstract available.
8.
Mbiandjeu S, Siciliano A, Matte A, Federti E, Perduca M, Melisi D, et al.
Antioxidants (Basel)
. 2024 Apr;
13(4).
PMID: 38671902
Aging is characterized by increased oxidation and reduced efficiency of cytoprotective mechanisms. Nuclear factor erythroid-2-related factor (Nrf2) is a key transcription factor, controlling the expression of multiple antioxidant proteins. Here,...
9.
Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al.
Gastric Cancer
. 2024 Apr;
27(4):649-671.
PMID: 38634954
Background: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy...
10.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, et al.
BMC Cancer
. 2024 Apr;
24(1):436.
PMID: 38589856
Background: Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1-3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures...